PT  - JOURNAL ARTICLE
ED  - ,
TI  - Correction: Apatinib plus camrelizumab (anti-PD1 therapy, SHR-1210) for advanced osteosarcoma (APFAO) progressing after chemotherapy: a single-arm, open-label, phase 2 trial
AID  - 10.1136/jitc-2020-000798corr1
DP  - 2020 Jun 01
TA  - Journal for ImmunoTherapy of Cancer
PG  - e000798corr1
VI  - 8
IP  - 1
4099  - http://jitc.bmj.com/content/8/1/e000798corr1.short
4100  - http://jitc.bmj.com/content/8/1/e000798corr1.full
SO  - J Immunother Cancer2020 Jun 01; 8